-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Merck (NYSE: MRK, Merck is the corporate name of Merck & Co.
, Kenilworth, New Jersey) announced today that the company has completed the spin-off of Organon
.
Today is an important milestone for Merck and Ogalon
.
Organon has become an independent listed company with a broad portfolio of important drugs and products, and is fully prepared to achieve sustainable growth and value
The goal of Merck’s spin-off is to establish two patient-centric companies, strengthen strategic and operational focus, increase flexibility, simplify operating models, optimize capital structure and improve financial conditions
.
Merck believes that the spin-off will bring significant benefits to both Merck and Ogalon, and create value for Merck’s shareholders
Ogalon does not issue odd shares of ordinary shares in the distribution of shares
.
Instead, Merck’s ordinary shareholders received cash to replace the odd shares of Ogalon ordinary shares that they were originally entitled to